20 September 2022 in Nature Communications
Assessing individual responses to glucocorticoid drug therapies that compromise immune status and affect survival outcomes in neuro-oncology is a great challenge. Here we introduce a blood-based neutrophil dexamethasone methylation index (NDMI) that provides a measure of the epigenetic response of subjects to dexamethasone. This marker outperforms conventional approaches based on leukocyte composition as a marker of glucocorticoid response. The NDMI is associated with low CD4 T cells and the accumulation of monocytic myeloid-derived suppressor cells and also serves as prognostic factor in glioma survival. In a non-glioma population, the NDMI increases with a history of prednisone use. Therefore, it may also be informative in other conditions where glucocorticoids are employed. We conclude that DNA methylation remodeling within the peripheral immune compartment is a rich source of clinically relevant markers of glucocorticoid response.
28 December 2023 in Research Square
Glioblastomas (GBM) are lethal central nervous system cancers associated with tumor and systemic immunosuppression. Heterogeneous monocyte myeloid-derived suppressor cells (M-MDSC) are implicated in the altered immune response in GBM, but M-MDSC ontogeny and definitive phenotypic markers are unknown. Using single-cell transcriptomics, we revealed heterogeneity in blood M-MDSC from GBM subjects and an enrichment in a transcriptional state reminiscent of neutrophil-like monocytes (NeuMo), a newly described pathway of monopoiesis in mice. Human NeuMo gene expression and Neu-like deconvolution fraction algorithms were created to quantitate the enrichment of this transcriptional state in GBM subjects. NeuMo populations were also observed in M-MDSCs from lung and head and neck cancer subjects. Dexamethasone (DEX) and prednisone exposures increased the usage of Neu-like states, which were inversely associated with tumor purity and survival in isocitrate dehydrogenase wildtype (IDH WT) gliomas. Anti-inflammatory ZC3HA12/Regnase-1 transcripts were highly correlated with NeuMo expression in tumors and in blood M-MDSC from GBM, lung, and head and neck cancer subjects. Additional novel transcripts of immune-modulating proteins were identified. Collectively, these findings provide a framework for understanding the heterogeneity of M-MDSCs in GBM as cells with different clonal histories and may reshape approaches to study and therapeutically target these cells.
29 September 2026 in Journal of Alzheimer’s Disease
Background: In Alzheimer's disease (AD), tau protein aggregates to form neurofibrillary tangles (NFTs). The cellular changes favoring AD brain NFT formation remain incompletely understood. AD brains also display mitochondrial defects, including reduced mitochondrial DNA (mtDNA) copy number. Objective: We considered whether mtDNA depletion alters tau homeostasis. Methods: We assessed tau mRNA using short-read mRNA sequencing and PCR, and tau protein using immunochemistry, in SH-SY5Y cells with chronic mtDNA depletion (ρ0). Results: mtDNA depletion increased tau expression and resulted in alternatively spliced isoforms, elevated 4R and exon 4a-containing MAPT transcripts, and consistently detectable big tau protein. ρ0 cells also displayed an elevated MAPT exon 13 3’Untranslated Region (UTR): Coding DNA sequence (CDS) ratio. Phosphorylation at amino acid positions 217 and 181 decreased. Conclusions: Mitochondrial dysfunction affects tau expression, splicing, and 3’UTR retention while increasing tau protein levels and modifying its phosphorylation. These studies hold AD relevance as they provide evidence for a relationship between two AD-associated phenomena, defective mitochondrial function and altered MAPT regulation.